{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,10]],"date-time":"2026-07-10T14:17:43Z","timestamp":1783693063003,"version":"3.55.0"},"reference-count":39,"publisher":"Springer Science and Business Media LLC","issue":"4","license":[{"start":{"date-parts":[[2026,5,7]],"date-time":"2026-05-07T00:00:00Z","timestamp":1778112000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2026,5,7]],"date-time":"2026-05-07T00:00:00Z","timestamp":1778112000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"funder":[{"DOI":"10.13039\/501100007374","name":"Universidade Federal De Minas Gerais","doi-asserted-by":"crossref","id":[{"id":"10.13039\/501100007374","id-type":"DOI","asserted-by":"crossref"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Ther Innov Regul Sci"],"published-print":{"date-parts":[[2026,7]]},"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:sec>\n                    <jats:title>Background<\/jats:title>\n                    <jats:p>Emerging therapies for multiple myeloma (MM) have significantly improved patient outcomes extending survival and advancing treatment toward more targeted, effective, and less toxic approaches. However, the disease remains incurable.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Objectives<\/jats:title>\n                    <jats:p>Analyze the therapeutic landscape of MM by evaluating drug candidates in clinical trials from 2014 to 2024.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods<\/jats:title>\n                    <jats:p>Data were extracted from ClinicalTrials.gov (CTG) and Cortellis Drug Discovery Intelligence (CDDI), including active and completed studies with results on newly diagnosed and refractory MM. Joinpoint regression models estimated Annual Percent Changes (APCs) and Average Annual Percent Changes (AAPC). Data were examined by clinical trial characteristics, targeting strategies, and potential impact on treatment advancements.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>\n                      A total of 1091 trials from CDDI and 1947 from CTG were screened, yielding 365 studies eligible for detailed analysis. Phase I trials were the most common (\n                      <jats:italic>n<\/jats:italic>\n                      \u2009=\u2009182; 49.9%), and biologic agents represented the majority of the investigational therapies (\n                      <jats:italic>n<\/jats:italic>\n                      \u2009=\u2009251; 68.8%). Among intervention types, cell therapies were predominant (\n                      <jats:italic>n<\/jats:italic>\n                      \u2009=\u2009171; 46.8%), with CAR-T products targeting BCMA (\n                      <jats:italic>n<\/jats:italic>\n                      \u2009=\u2009107), CD19 (\n                      <jats:italic>n<\/jats:italic>\n                      \u2009=\u200916), and GPRC5D (\n                      <jats:italic>n<\/jats:italic>\n                      \u2009=\u200912) emerging as the most studied in recent years. Before the joinpoint, the number of active trials grew by 1.86% per year (95% CI: 1.67\u20132.06), corresponding to an average increase of 11.9 studies annually. After the joinpoint, growth accelerated to 3.69% per year (95% CI: 3.19\u20134.19), equivalent to 26.5 additional trials each year. Across the entire study period, the weighted average annual percentage change (AAPC) was 2.63%.\n                    <\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusion<\/jats:title>\n                    <jats:p>The rise in MM clinical trials highlights a shift toward biologic therapies, particularly immunotherapies and gene therapies like CAR-T.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1007\/s43441-026-00971-7","type":"journal-article","created":{"date-parts":[[2026,5,7]],"date-time":"2026-05-07T17:32:42Z","timestamp":1778175162000},"page":"1171-1185","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":0,"title":["Therapeutic Horizon in Multiple Myeloma: Analysis of the Emerging Landscape of Clinical Trials"],"prefix":"10.1007","volume":"60","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-6269-8745","authenticated-orcid":false,"given":"Marina Alacoque","family":"Rodrigues","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-7083-3188","authenticated-orcid":false,"given":"Cristiane Aparecida Menezes","family":"de P\u00e1dua","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-4639-7424","authenticated-orcid":false,"given":"Paula Lana","family":"de Miranda Drummond","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-4610-393X","authenticated-orcid":false,"given":"J\u00e9ssica Soares","family":"Malta","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-0017-7338","authenticated-orcid":false,"given":"Adriano Max Moreira","family":"Reis","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2026,5,7]]},"reference":[{"issue":"12","key":"971_CR1","doi-asserted-by":"publisher","first-page":"e74970","DOI":"10.7759\/cureus.74970","volume":"16","author":"E Zavaleta-Monestel","year":"2024","unstructured":"Zavaleta-Monestel E, Quesada-Villase\u00f1or R, Barrantes-L\u00f3pez M, et al. Advancements in the treatment of multiple myeloma. Cureus. 2024;16(12):e74970. https:\/\/doi.org\/10.7759\/cureus.74970.","journal-title":"Cureus"},{"issue":"6","key":"971_CR2","doi-asserted-by":"publisher","first-page":"829","DOI":"10.1007\/s10585-024-10305-2","volume":"41","author":"MH Elbahoty","year":"2024","unstructured":"Elbahoty MH, Papineni B, Samant RS. Multiple myeloma: clinical characteristics, current therapies and emerging innovative treatments targeting ribosome biogenesis dynamics. Clin Exp Metastasis. 2024;41(6):829\u201342. https:\/\/doi.org\/10.1007\/s10585-024-10305-2.","journal-title":"Clin Exp Metastasis"},{"key":"971_CR3","doi-asserted-by":"publisher","first-page":"20705","DOI":"10.1038\/s41598-023-47906-y","volume":"13","author":"SE Mousavi","year":"2023","unstructured":"Mousavi SE, Ilaghi M, Aslani A, et al. A population-based study on incidence trends of myeloma in the United States over 2000\u20132020. Sci Rep. 2023;13:20705. https:\/\/doi.org\/10.1038\/s41598-023-47906-y.","journal-title":"Sci Rep"},{"issue":"Suppl 1","key":"971_CR4","doi-asserted-by":"publisher","first-page":"62","DOI":"10.1002\/hon.2586","volume":"37","author":"SV Rajkumar","year":"2019","unstructured":"Rajkumar SV. Multiple myeloma: every year a new standard? Hematol Oncol. 2019;37(Suppl 1):62\u20135. https:\/\/doi.org\/10.1002\/hon.2586.","journal-title":"Hematol Oncol"},{"key":"971_CR5","first-page":"1096","volume":"5","author":"S Jagannath","year":"2021","unstructured":"Jagannath S, Mikhael J, Nadeem O, et al. Digital health for patients with multiple myeloma: an unmet need. JCO Clin Cancer Inf. 2021;5:1096\u2013105.","journal-title":"JCO Clin Cancer Inf"},{"issue":"1","key":"971_CR6","doi-asserted-by":"publisher","first-page":"23","DOI":"10.1158\/1078-0432.CCR-21-1069","volume":"28","author":"PM Voorhees","year":"2022","unstructured":"Voorhees PM, Jakubowiak AJ, Kumar SK, et al. Perspectives on drug development in multiple myeloma\u2013looking forward to 2025. Clin Cancer Res. 2022;28(1):23\u20136. https:\/\/doi.org\/10.1158\/1078-0432.CCR-21-1069.","journal-title":"Clin Cancer Res"},{"issue":"1","key":"971_CR7","doi-asserted-by":"publisher","first-page":"150","DOI":"10.1186\/s13045-020-00980-5","volume":"13","author":"Y Yang","year":"2020","unstructured":"Yang Y, Li Y, Gu H, Dong M, Cai Z. Emerging agents and regimens for multiple myeloma. J Hematol Oncol. 2020;13(1):150. https:\/\/doi.org\/10.1186\/s13045-020-00980-5.","journal-title":"J Hematol Oncol"},{"key":"971_CR8","doi-asserted-by":"publisher","first-page":"6192","DOI":"10.3390\/ijms25116192","volume":"25","author":"C-HT Lin","year":"2024","unstructured":"Lin C-HT, Tariq MJ, Ullah F, et al. Current novel targeted therapeutic strategies in multiple myeloma. Int J Mol Sci. 2024;25:6192. https:\/\/doi.org\/10.3390\/ijms25116192.","journal-title":"Int J Mol Sci"},{"issue":"3","key":"971_CR9","doi-asserted-by":"publisher","first-page":"488","DOI":"10.1111\/bjh.17805","volume":"196","author":"D Swan","year":"2022","unstructured":"Swan D, Routledge D, Harrison S. The evolving status of immunotherapies in multiple myeloma: the future role of bispecific antibodies. Br J Haematol. 2022;196(3):488\u2013506. https:\/\/doi.org\/10.1111\/bjh.17805.","journal-title":"Br J Haematol"},{"issue":"1","key":"971_CR10","doi-asserted-by":"publisher","first-page":"206","DOI":"10.1038\/s41408-024-01191-8","volume":"14","author":"D Swan","year":"2024","unstructured":"Swan D, Madduri D, Hocking J. CAR-T cell therapy in multiple myeloma: current status and future challenges. Blood Cancer J. 2024;14(1):206. https:\/\/doi.org\/10.1038\/s41408-024-01191-8.","journal-title":"Blood Cancer J"},{"issue":"8","key":"971_CR11","doi-asserted-by":"publisher","first-page":"e2014682","DOI":"10.1001\/jamanetworkopen.2020.14682","volume":"3","author":"G Gresham","year":"2020","unstructured":"Gresham G, Meinert JL, Gresham AG, Meinert CL. Assessment of trends in the design, accrual, and completion of trials registered in ClinicalTrials.gov by sponsor type, 2000\u20132019. JAMA Netw Open. 2020;3(8):e2014682. https:\/\/doi.org\/10.1001\/jamanetworkopen.2020.14682.","journal-title":"JAMA Netw Open"},{"issue":"6","key":"971_CR12","doi-asserted-by":"publisher","first-page":"5932","DOI":"10.3390\/curroncol30060443","volume":"30","author":"BM Henry","year":"2023","unstructured":"Henry BM, Lippi G, Nasser A, Ostrowski P. Characteristics of Phase IV clinical trials in oncology: an analysis using the ClinicalTrials.gov registry data. Curr Oncol. 2023;30(6):5932\u201345. https:\/\/doi.org\/10.3390\/curroncol30060443.","journal-title":"Curr Oncol"},{"issue":"1","key":"971_CR13","doi-asserted-by":"publisher","first-page":"30","DOI":"10.1186\/s12885-023-11690-9","volume":"24","author":"S Zhao","year":"2024","unstructured":"Zhao S, Miao M, Wang Q, et al. The current status of clinical trials on cancer and age disparities among the most common cancer trial participants. BMC Cancer. 2024;24(1):30. https:\/\/doi.org\/10.1186\/s12885-023-11690-9.","journal-title":"BMC Cancer"},{"key":"971_CR14","doi-asserted-by":"publisher","first-page":"100953","DOI":"10.1016\/j.conctc.2022.100953","volume":"28","author":"D Stani\u0161i\u0107","year":"2022","unstructured":"Stani\u0161i\u0107 D, Osmanovi\u0107 A, Fojnica A, Kurtovi\u0107-Kozari\u0107 A. Clinical trials in Bosnia and Herzegovina: challenges and future perspectives. Contemp Clin Trials Commun. 2022;28:100953. https:\/\/doi.org\/10.1016\/j.conctc.2022.100953.","journal-title":"Contemp Clin Trials Commun"},{"issue":"10","key":"971_CR15","doi-asserted-by":"publisher","first-page":"2957","DOI":"10.7150\/jca.43521","volume":"11","author":"J Xu","year":"2020","unstructured":"Xu J, Lin Y, Yang M, Zhang L. Statistics and pitfalls of trend analysis in cancer research: a review focused on statistical packages. J Cancer. 2020;11(10):2957\u201361. https:\/\/doi.org\/10.7150\/jca.43521.","journal-title":"J Cancer"},{"issue":"4","key":"971_CR16","doi-asserted-by":"publisher","first-page":"e0121054","DOI":"10.1371\/journal.pone.0121054","volume":"10","author":"BT Hung","year":"2015","unstructured":"Hung BT, Long NP, Hung LP, et al. Research trends in evidence-based medicine: a joinpoint regression analysis of more than 50 years of publication data. PLoS ONE. 2015;10(4):e0121054. https:\/\/doi.org\/10.1371\/journal.pone.0121054.","journal-title":"PLoS ONE"},{"issue":"2","key":"971_CR17","doi-asserted-by":"publisher","first-page":"511","DOI":"10.1016\/j.hoc.2023.12.013","volume":"38","author":"N Abdallah","year":"2024","unstructured":"Abdallah N, Kumar SK. New therapies on the horizon for relapsed refractory multiple myeloma. Hematol Oncol Clin North Am. 2024;38(2):511\u201332. https:\/\/doi.org\/10.1016\/j.hoc.2023.12.013.","journal-title":"Hematol Oncol Clin North Am"},{"issue":"4","key":"971_CR18","doi-asserted-by":"publisher","first-page":"239","DOI":"10.1038\/d41573-024-00048-w","volume":"23","author":"A Mullard","year":"2024","unstructured":"Mullard A. Shifts in the clinical trial landscape. Nat Rev Drug Discov. 2024;23(4):239. https:\/\/doi.org\/10.1038\/d41573-024-00048-w.","journal-title":"Nat Rev Drug Discov"},{"issue":"2","key":"971_CR19","doi-asserted-by":"publisher","first-page":"59","DOI":"10.4103\/picr.picr_44_25","volume":"16","author":"VS Jaguste","year":"2025","unstructured":"Jaguste VS. Disruption of healthcare delivery and clinical trial operations during COVID-19: lessons learned, planning for solutions. Perspect Clin Res. 2025;16(2):59\u201360. https:\/\/doi.org\/10.4103\/picr.picr_44_25.","journal-title":"Perspect Clin Res"},{"issue":"22","key":"971_CR20","doi-asserted-by":"publisher","first-page":"3867","DOI":"10.3390\/cancers16223867","volume":"16","author":"S Vera-Cruz","year":"2024","unstructured":"Vera-Cruz S, Jornet Culubret M, Konetzki V, et al. Cellular therapies for multiple myeloma: engineering hope. Cancers. 2024;16(22):3867. https:\/\/doi.org\/10.3390\/cancers16223867.","journal-title":"Cancers"},{"issue":"19","key":"971_CR21","doi-asserted-by":"publisher","first-page":"4787","DOI":"10.3390\/cancers13194787","volume":"13","author":"J Ackley","year":"2021","unstructured":"Ackley J, Ochoa MA, Ghoshal D, et al. Keeping myeloma in check: the past, present and future of immunotherapy in multiple myeloma. Cancers (Basel). 2021;13(19):4787. https:\/\/doi.org\/10.3390\/cancers13194787.","journal-title":"Cancers (Basel)"},{"issue":"5","key":"971_CR22","doi-asserted-by":"publisher","first-page":"768","DOI":"10.1182\/bloodadvances.2022007210","volume":"7","author":"MJ Frigault","year":"2023","unstructured":"Frigault MJ, Bishop MR, Rosenblatt J, et al. Phase 1 study of CART-ddBCMA for the treatment of subjects with relapsed and refractory multiple myeloma. Blood Adv. 2023;7(5):768\u201377. https:\/\/doi.org\/10.1182\/bloodadvances.2022007210.","journal-title":"Blood Adv"},{"issue":"Suppl 2","key":"971_CR23","doi-asserted-by":"publisher","first-page":"S13","DOI":"10.1002\/ajh.26628","volume":"98","author":"G Ravi","year":"2023","unstructured":"Ravi G, Costa LJ. Bispecific T-cell engagers for treatment of multiple myeloma. Am J Hematol. 2023;98(Suppl 2):S13\u201321. https:\/\/doi.org\/10.1002\/ajh.26628.","journal-title":"Am J Hematol"},{"issue":"22","key":"971_CR24","doi-asserted-by":"publisher","first-page":"2702","DOI":"10.1200\/JCO.24.01008","volume":"42","author":"N Bumma","year":"2024","unstructured":"Bumma N, Richter J, Jagannath S, et al. Linvoseltamab for treatment of relapsed\/refractory multiple myeloma. J Clin Oncol. 2024;42(22):2702\u201312. https:\/\/doi.org\/10.1200\/JCO.24.01008.","journal-title":"J Clin Oncol"},{"issue":"11","key":"971_CR25","doi-asserted-by":"publisher","first-page":"762","DOI":"10.1016\/j.clml.2024.06.004","volume":"24","author":"TH Patel","year":"2024","unstructured":"Patel TH, van Rhee F, Al Hadidi S. Cereblon E3 ligase modulators mezigdomide and iberdomide in multiple myeloma. Clin Lymphoma Myeloma Leuk. 2024;24(11):762\u20139. https:\/\/doi.org\/10.1016\/j.clml.2024.06.004.","journal-title":"Clin Lymphoma Myeloma Leuk"},{"issue":"Suppl 1","key":"971_CR26","doi-asserted-by":"publisher","first-page":"1815","DOI":"10.1182\/blood-2019-124345","volume":"134","author":"L Wong","year":"2019","unstructured":"Wong L, Narla RK, Leisten J, et al. CC-92480, a novel cereblon E3 ligase modulator, is synergistic with dexamethasone, bortezomib, and daratumumab in multiple myeloma. Blood. 2019;134(Suppl 1):1815. https:\/\/doi.org\/10.1182\/blood-2019-124345.","journal-title":"Blood"},{"issue":"11","key":"971_CR27","doi-asserted-by":"publisher","first-page":"1009","DOI":"10.1056\/NEJMoa2303194","volume":"389","author":"PG Richardson","year":"2023","unstructured":"Richardson PG, Trudel S, Popat R, et al. Mezigdomide plus dexamethasone in relapsed and refractory multiple myeloma. N Engl J Med. 2023;389(11):1009\u201322. https:\/\/doi.org\/10.1056\/NEJMoa2303194.","journal-title":"N Engl J Med"},{"issue":"2","key":"971_CR28","doi-asserted-by":"publisher","first-page":"535","DOI":"10.1021\/acs.jmedchem.6b01921","volume":"61","author":"ME Matyskiela","year":"2018","unstructured":"Matyskiela ME, Zhang W, Man HW, et al. A cereblon modulator (CC-220) with improved degradation of Ikaros and Aiolos. J Med Chem. 2018;61(2):535\u201342. https:\/\/doi.org\/10.1021\/acs.jmedchem.6b01921.","journal-title":"J Med Chem"},{"issue":"13","key":"971_CR29","doi-asserted-by":"publisher","first-page":"6648","DOI":"10.1021\/acs.jmedchem.9b01928","volume":"63","author":"JD Hansen","year":"2020","unstructured":"Hansen JD, Correa M, Nagy MA, et al. Discovery of CRBN E3 ligase modulator CC-92480 for the treatment of relapsed and refractory multiple myeloma. J Med Chem. 2020;63(13):6648\u201376. https:\/\/doi.org\/10.1021\/acs.jmedchem.9b01928.","journal-title":"J Med Chem"},{"key":"971_CR30","doi-asserted-by":"publisher","first-page":"2","DOI":"10.1186\/s40364-020-0182-y","volume":"8","author":"S Gao","year":"2020","unstructured":"Gao S, Wang S, Song Y. Novel immunomodulatory drugs and neo-substrates. Biomark Res. 2020;8:2. https:\/\/doi.org\/10.1186\/s40364-020-0182-y.","journal-title":"Biomark Res"},{"issue":"2","key":"971_CR31","doi-asserted-by":"publisher","first-page":"904","DOI":"10.3390\/ijms23020904","volume":"23","author":"E Verheye","year":"2022","unstructured":"Verheye E, Bravo Melgar J, Deschoemaeker S, Raes G, Maes A, De Bruyne E, et al. Dendritic cell-based immunotherapy in multiple myeloma: challenges, opportunities, and future directions. Int J Mol Sci. 2022;23(2):904. https:\/\/doi.org\/10.3390\/ijms23020904.","journal-title":"Int J Mol Sci"},{"key":"971_CR32","doi-asserted-by":"publisher","first-page":"109168","DOI":"10.1016\/j.clim.2022.109168","volume":"246","author":"E Roshandel","year":"2023","unstructured":"Roshandel E, Ghaffari-Nazari H, Mohammadian M, Salimi M, Abroun S, Mirfakhraie R, Hajifathali A. NK cell therapy in relapsed refractory multiple myeloma. Clin Immunol. 2023;246:109168. https:\/\/doi.org\/10.1016\/j.clim.2022.109168.","journal-title":"Clin Immunol"},{"key":"971_CR33","doi-asserted-by":"publisher","first-page":"2031","DOI":"10.1080\/1042819031000116599","volume":"44","author":"Q Yi","year":"2003","unstructured":"Yi Q. Dendritic cell-based immunotherapy in multiple myeloma. Leuk Lymphoma. 2003;44:2031\u20138. https:\/\/doi.org\/10.1080\/1042819031000116599.","journal-title":"Leuk Lymphoma"},{"key":"971_CR34","doi-asserted-by":"publisher","first-page":"397648","DOI":"10.1155\/2012\/397648","volume":"2012","author":"TN Nguyen-Pham","year":"2012","unstructured":"Nguyen-Pham TN, Lee YK, Kim HJ, Lee JJ. Immunotherapy using dendritic cells against multiple myeloma: how to improve? Clin Dev Immunol. 2012;2012:397648. https:\/\/doi.org\/10.1155\/2012\/397648.","journal-title":"Clin Dev Immunol"},{"key":"971_CR35","doi-asserted-by":"publisher","first-page":"e2200119","DOI":"10.1200\/GO.22.00119","volume":"8","author":"RA Fatoki","year":"2022","unstructured":"Fatoki RA, Koehn K, Kelkar A, Al Hadidi S, Mehra N, Mian H, Landgren O, Kazandjian D, Hoffman J, Sborov DW, Mohyuddin GR. Global myeloma trial participation and drug access in the era of novel therapies. JCO Glob Oncol. 2022;8:e2200119. https:\/\/doi.org\/10.1200\/GO.22.00119.","journal-title":"JCO Glob Oncol"},{"key":"971_CR36","unstructured":"US Food and Drug Administration. Code of Federal Regulations Title 21 (21 CFR). Part 601, Subpart A and E; Part 314, Subpart B. and H. Available from: https:\/\/www.ecfr.gov\/current\/title-21\/chapter-I\/subchapter-F\/part-601\/subpart-E. Accessed 13 April\u00a0 2025."},{"key":"971_CR37","doi-asserted-by":"publisher","first-page":"151","DOI":"10.1016\/j.jclinepi.2023.04.001","volume":"159","author":"TB Ribeiro","year":"2023","unstructured":"Ribeiro TB, Bennett CL, Colunga-Lozano LE, et al. Increasing FDA-accelerated approval of single-arm trials in oncology (1992 to 2020). J Clin Epidemiol. 2023;159:151\u20138. https:\/\/doi.org\/10.1016\/j.jclinepi.2023.04.001.","journal-title":"J Clin Epidemiol"},{"issue":"7","key":"971_CR38","doi-asserted-by":"publisher","first-page":"2519","DOI":"10.3390\/jcm14072519","volume":"14","author":"G Joshi","year":"2025","unstructured":"Joshi G, Bhandari TK, Joshi P, et al. The current landscape of clinical trials. J Clin Med. 2025;14(7):2519. https:\/\/doi.org\/10.3390\/jcm14072519.","journal-title":"J Clin Med"},{"issue":"1","key":"971_CR39","doi-asserted-by":"publisher","first-page":"19","DOI":"10.1038\/nrd.2017.194","volume":"17","author":"HP Shih","year":"2018","unstructured":"Shih HP, Zhang X, Aronov AM. Drug discovery effectiveness from the standpoint of therapeutic mechanisms and indications. Nat Rev Drug Discov. 2018;17(1):19\u201333. https:\/\/doi.org\/10.1038\/nrd.2017.194.","journal-title":"Nat Rev Drug Discov"}],"container-title":["Therapeutic Innovation &amp; Regulatory Science"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s43441-026-00971-7.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s43441-026-00971-7","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s43441-026-00971-7.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,7,10]],"date-time":"2026-07-10T13:49:49Z","timestamp":1783691389000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s43441-026-00971-7"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,5,7]]},"references-count":39,"journal-issue":{"issue":"4","published-print":{"date-parts":[[2026,7]]}},"alternative-id":["971"],"URL":"https:\/\/doi.org\/10.1007\/s43441-026-00971-7","relation":{},"ISSN":["2168-4790","2168-4804"],"issn-type":[{"value":"2168-4790","type":"print"},{"value":"2168-4804","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,5,7]]},"assertion":[{"value":"23 July 2025","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"19 April 2026","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"7 May 2026","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"This study relied exclusively on publicly available data. In accordance with Brazilian national regulations (National Health Council [CNS] Resolution No. 510, of April 7, 2016, Article 1st ), research utilizing publicly accessible information that does not directly involve human subjects, or identifiable personal data is automatically exempt from ethical review.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics Approval"}},{"value":"This study consists of databases\u2019 analysis, therefore no consent to participate is required.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent to Participate"}},{"value":"The authors declare no competing interests.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}]}}